Apr 29, 2009 by Brian Orelli, PhDThe Other 33.1% of Pfizer ReportsWyeth reports earnings, but investors need only look at the top line.
Apr 29, 2009 by Brian Orelli, PhDParachutes, Cliffs, and Softer LandingsBristol-Myers gets ready to fly -- or fall.
Apr 27, 2009 by Brian Orelli, PhDJohnson & Johnson's Simponi Sticks to the WallJohnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA.
Apr 24, 2009 by Brian Orelli, PhDGreat Drugs Not Living Up to Their PotentialDrugs that work don't always become blockbusters.
Apr 23, 2009 by Brian Orelli, PhDHitting the Patent Cliff EarlyThe bottom hurts, but at least Glaxo can brush off and recover.
Apr 22, 2009 by Brian Orelli, PhDIlluminating Stock Option ProblemsSlow down the employee rewards, Illumina.
Apr 22, 2009 by Brian Orelli, PhDYou Left Out the Kitchen Sink, KCKnietic Concepts says: You want it? You got it.
Apr 21, 2009 by Brian Orelli, PhDSchering and Merck: A Match Made in PurgatoryMerck needs Schering, and Schering has to sit there and take it.
Apr 21, 2009 by Brian Orelli, PhDReworking the Broken R&D Model Collaborations will help bring drugs to the market more cheaply.
Apr 20, 2009 by Brian Orelli, PhDA Cheer and a Boo for Eli LillyThe company cuts costs, but the patent cliff is still close.
